Sanofi Seeks Further FDA Input Following Zimulti NDA Withdrawal
Executive Summary
Sanofi-Aventis intends to resubmit its NDA for Zimulti (rimonabant) pending clarification of FDA's questions regarding its obesity claim. The firm announced it was withdrawing the application June 29, roughly two weeks after the agency's Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted against approval of the cannabinoid-1 receptor antagonist for weight loss
You may also be interested in...
Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug
Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug
Sanofi-Aventis Expands Rimonabant Diabetes Program With Multiple Trials
Sanofi-Aventis is expanding its Zimulti (rimonabant) diabetes program after clinical study results showed the drug's effectiveness in reducing HbA1c is comparable to oral anti-diabetics